We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Eli Lilly And Co | LSE:0Q1G | London | Ordinary Share | ELI LILLY ORD SHS |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | USD 34.12B | USD 5.24B | USD 5.5202 | 134.81 | 77.68B |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
15:34:41 | O | 1 | 58,643.38 | CHF |
Date | Time | Source | Headline |
---|---|---|---|
30/10/2024 | 12:24 | ALNC | TOP NEWS: Eli Lilly returns to profit in quarter, downgrades guidance |
09/9/2024 | 11:16 | ALNC | Eli Lilly names Lucas Montarce as new chief financial officer |
08/8/2024 | 11:57 | ALNC | TOP NEWS: Eli Lilly lifts guidance as Mounjaro and Zepbound sales jump |
08/7/2024 | 18:58 | ALNC | Eli Lilly weight loss drug beats Ozempic in head-to-head study |
05/6/2024 | 13:00 | ALNC | TOP NEWS: Alphabet poaches Eli Lilly CFO Anat Ashkenazi for same role |
21/5/2024 | 12:14 | ALNC | *Eli Lilly: over half of Crohn's disease patients reach remission at 1 year.. |
15/5/2024 | 20:07 | ALNC | Eli Lilly reaches settlement with Totality Medispa |
30/4/2024 | 12:26 | ALNC | TOP NEWS: Eli Lilly lifts outlook, ramps up production to meet demand |
08/3/2024 | 15:16 | ALNC | Eli Lilly's Donanemab Alzheimer's drug hit by delays |
06/2/2024 | 12:44 | ALNC | TOP NEWS: Eli Lilly eyes beefier sales amid weight loss drug craze |
Eli Lilly (0Q1G) Share Charts1 Year Eli Lilly Chart |
|
1 Month Eli Lilly Chart |
Intraday Eli Lilly Chart |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|---|---|---|---|
15:34:42 | 58,643.38 | 1 | 0.00 | O |
15:20:21 | 58,928.10 | 5 | 0.00 | O |
15:19:31 | 58,846.86 | 5 | 0.00 | O |
15:10:07 | 58,611.66 | 8 | 0.00 | O |
15:07:46 | 58,388.78 | 7 | 0.00 | O |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions